A de novo diabetes mellitus a májátültetés gyakori szövődménye. Célkitűzés: A de novo diabetes gyakoriságát, jelentőségét és a kockázati tényezők szerepét vizsgáltuk. Módszer: 1995 és 2009 között 310 májátültetett beteg adatait dolgoztuk fel retrospektív módszerrel. De novo diabetest állapítottunk meg, ha az éhomi vércukor a 3. posztoperatív hónapon túl ismételten >6,8 mmol/l volt, és/vagy a májátültetés után tartós, a 3. posztoperatív hónapot meghaladóan is fenntartott antidiabetikus terápia indult. Eredmények: De novo diabetes a betegek 20%-ánál (63 beteg) alakult ki. A de novo és a kontrollcsoport között az alábbiakban találtunk különbséget. Donor-testtömegindex (24±3 vs. 22,4±3,6 kg/m 2 , p = 0,003), férfi nem (58% vs. 33%, p = 0,002). Recipienséletkor (47,6±7,2 vs. 38,3±14,6 év, p<0,001), -testtömegindex (26,7±3,8 vs. 23,3±5,6 kg/m 2 , p<0,001), férfi nem (60% vs. 44%, p = 0,031). A de novo diabetesesek csoportjában a betegek 66%-át HCV talaján kialakult cirrhosis miatt transzplantálták, a kontrollcsoportban ez csak 23% volt (p<0,001). Az 1, 3, 5 és 8 éves kumulatív betegtúlélés a kontrollcsoportban 95%, 91%, 88% és 88%, a de novo csoportban a megfelelő értékek 87%, 79%, 79% és 64% (p = 0,011). Az 1, 3, 5 és 8 éves kumulatív grafttúlélés a kontrollcsoportban 92%, 87%, 86% és 79%, a de novo csoportban a megfelelő értékek 87%, 79%, 79%, 65% (p = NS). Azoknál a betegeknél, akiknél a C-vírus korai (6 hónapon belüli) kiújulását észleltük, többségben de novo diabetes is kialakult (74% vs. kontroll 26%, p = 0,03). A betegek 53%-ában észleltünk tízszeres vírustiter-emelkedést a műtét utáni 6 hónapon belül a preoperatív értékhez viszonyítva diabetes kialakulása esetén, a kontrollnál ez 20% volt (p = 0,028). A de novo csoportban magasabb volt az átlagos (Ishak-Knodell) fibrosis score az antivirális kezelés megkezdését követően 1 évvel (2,05±1,53 vs. 1,00±1,08, p = 0,039). Következtetés: Májátültetést követő de novo diabetes kockázati tényezői az időskor, elhízás, férfi nem és a C-vírus okozta cirrhosis. Víruspozitív betegek körében a korai rekurrencia, súlyosabb viraemia és az antivirális kezelés ellenére kialakuló súlyosabb fibrosis összefügg a de novo diabetes kialakulásával.
Picardi, A., D’Avola, D., Gentilucci, U. V. és mtsai: Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab. Res. Rev., 2006, 22 , 274–283.
Gentilucci U. V. , 'Diabetes in chronic liver disease: from old concepts to new evidence ' (2006 ) 22 Diabetes Metab. Res. Rev. : 274 -283 .
Perseghin, G., Mazzaferro, V., Sereni, L. P. és mtsai: Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. Hepatology, 2000, 31 , 694–703.
Sereni L. P. , 'Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation ' (2000 ) 31 Hepatology : 694 -703 .
Bigam, D. L., Pennington, J. J., Carpentier, A. és mtsai: Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology, 2000, 32 , 87–90.
Carpentier A. , 'Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation ' (2000 ) 32 Hepatology : 87 -90 .
Garcia-Compean, D., Jaquez-Quintana, J. O., Maldonado-Garza, H.: Hepatogenous diabetes. Current views of an ancient problem. Ann. Hepatol., 2009, 8 , 13–20.
Maldonado-Garza H. , 'Hepatogenous diabetes. Current views of an ancient problem ' (2009 ) 8 Ann. Hepatol. : 13 -20 .
Neuschwander-Tetri, B. A., Caldwell, S. H.: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology, 2003, 37 , 1202–1219.
Caldwell S. H. , 'Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference ' (2003 ) 37 Hepatology : 1202 -1219 .
Saliba, F., Lakehal, M., Pageaux, G. P. és mtsai: Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl., 2007, 13 , 136–144.
Pageaux G. P. , 'Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study ' (2007 ) 13 Liver Transpl. : 136 -144 .
Khalili, M., Lim, J. W., Bass, N. és mtsai: New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl., 2004, 10 , 349–355.
Bass N. , 'New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection ' (2004 ) 10 Liver Transpl. : 349 -355 .
Lladó, L., Xiol, X., Figueras, J. és mtsai: Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. Journal of Hepatology, 2006, 44 , 710–716.
Figueras J. , 'Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study ' (2006 ) 44 Journal of Hepatology : 710 -716 .
Benhamou, P. Y., Penformis, A.: Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab., 2002, 28 , 166–175.
Penformis A. , 'Natural history, prognosis, and management of transplantation-induced diabetes mellitus ' (2002 ) 28 Diabetes Metab. : 166 -175 .
Moscatiello, S., Manini, R., Marchesini, G.: Diabetes and liver disease: An ominous association. Nutrition, Metabolism & Cardiovascular Diseases, 2007, 17 , 63–70.
Marchesini G. , 'Diabetes and liver disease: An ominous association ' (2007 ) 17 Nutrition, Metabolism & Cardiovascular Diseases : 63 -70 .
AlDosary, A. A., Ramji, A. S., Elliott, T. G. és mtsai: Post-liver transplantation diabetes mellitus: An association with hepatitis C. Liver Transpl., 2002, 8 , 356–361.
Elliott T. G. , 'Post-liver transplantation diabetes mellitus: An association with hepatitis C ' (2002 ) 8 Liver Transpl. : 356 -361 .
Nemes B., Sárváry E., Kóbori L. és mtsai: A hazai májátültetési program demográfiai, perioperatív és mortalitási adatai. Orv. Hetil., 2005, 146 , 1423–1432.
Kóbori L. , 'A hazai májátültetési program demográfiai, perioperatív és mortalitási adatai ' (2005 ) 146 Orv. Hetil. : 1423 -1432 .
Fehérvári I., Görög D., Kóbori L. és mtsai: Hepatitis B és májtranszplantáció. Orv. Hetil., 2007, 148 , 1299–1302.
Kóbori L. , 'Hepatitis B és májtranszplantáció ' (2007 ) 148 Orv. Hetil. : 1299 -1302 .
Nemes B., Zádori G., Hartmann E. és mtsai: Epeúti szövődmények májtranszplantáció után. Orv. Hetil., 2008, 149 , 963–973.
Hartmann E. , 'Epeúti szövődmények májtranszplantáció után ' (2008 ) 149 Orv. Hetil. : 963 -973 .
Nemes B., Gelley F., Zádori G. és mtsai: Marginális donorok szerepe a magyar májátültetési programban. Orv. Hetil., 2009, 150 , 2228–2236.
Zádori G. , 'Marginális donorok szerepe a magyar májátültetési programban ' (2009 ) 150 Orv. Hetil. : 2228 -2236 .
Shah, A., Kendall, G., Demme, R. A. és mtsai: Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. Transplantation, 2005, 80 , 775–781.
Demme R. A. , 'Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients ' (2005 ) 80 Transplantation : 775 -781 .
Gabir, M. M., Hanson, R. L., Dabelea, D. és mtsai: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care, 2000, 23 , 1108–1112.
Dabelea D. , 'The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes ' (2000 ) 23 Diabetes Care : 1108 -1112 .
Marchetti, P.: New-onset diabetes after liver transplantation: From pathogenesis to management. Liver Transpl., 2005, 11 , 612–620.
Marchetti P. , 'New-onset diabetes after liver transplantation: From pathogenesis to management ' (2005 ) 11 Liver Transpl. : 612 -620 .
Tietge, U. J., Selberg, O., Kreter, A. és mtsai: Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl., 2004, 10 , 1030–1040.
Kreter A. , 'Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation ' (2004 ) 10 Liver Transpl. : 1030 -1040 .
Thuluvath, P. J.: Is there a link between hepatitis C virus and new onset of diabetes mellitus after liver transplantation? Liver Transpl., 2007, 13 , 5–7.
Thuluvath P. J. , 'Is there a link between hepatitis C virus and new onset of diabetes mellitus after liver transplantation? ' (2007 ) 13 Liver Transpl. : 5 -7 .
Davidson, J. A., Wilkinson, A.: New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view. Diabetes Care, 2004, 27 , 805–812.
Wilkinson A. , 'New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view ' (2004 ) 27 Diabetes Care : 805 -812 .
Samurani, N. B., Delaney, V., Ding, Z. és mtsai: Diabetes mellitus after renal transplantation in the cyclosporine era – An analysis of risk factors. Transplantation, 1991, 51 , 343–347.
Ding Z. , 'Diabetes mellitus after renal transplantation in the cyclosporine era – An analysis of risk factors ' (1991 ) 51 Transplantation : 343 -347 .
Ladowski, J. S., Kormos, R. L., Uretsky, B. F. és mtsai: Posttransplantation diabetes mellitus in heart transplant recipients. J. Heart Transplant., 1989, 8 , 181 –183.
Uretsky B. F. , 'Posttransplantation diabetes mellitus in heart transplant recipients ' (1989 ) 8 J. Heart Transplant. : 181 -183 .
Baid, S., Cosimi, A. B., Farrell, M. L. és mtsai: Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation, 2001, 72 , 1066–1072.
Farrell M. L. , 'Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality ' (2001 ) 72 Transplantation : 1066 -1072 .
Mirabella, S., Brunati, A., Ricchiuti, A. és mtsai: New-onset diabetes after liver transplantation. Transplantation Proceedings, 2005, 37 , 2636–2637.
Ricchiuti A. , 'New-onset diabetes after liver transplantation ' (2005 ) 37 Transplantation Proceedings : 2636 -2637 .
Nardo, B., Masetti, M., Urbani, L. és mtsai: Liver transplantation from donors aged 80 years and over: pushing the limit. Am. J. Transplant., 2004, 4 , 1139–1147.
Urbani L. , 'Liver transplantation from donors aged 80 years and over: pushing the limit ' (2004 ) 4 Am. J. Transplant. : 1139 -1147 .
Levy, G., Grazi, G. L., Sanjuan, F. és mtsai: 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl., 2006, 12 , 1464–1472.
Sanjuan F. , '12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus ' (2006 ) 12 Liver Transpl. : 1464 -1472 .
Ma, Y., Yan, W. W.: Chronic hepatitis C virus infection and post-transplantation diabetes mellitus. World J. Gastroenterol., 2005, 11 , 6085–6089.
Yan W. W. , 'Chronic hepatitis C virus infection and post-transplantation diabetes mellitus ' (2005 ) 11 World J. Gastroenterol. : 6085 -6089 .
McAlister, V. C., Haddad, E., Renouf, E. és mtsai: Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am. J. Transplant., 2006, 6 , 1578–1585.
Renouf E. , 'Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis ' (2006 ) 6 Am. J. Transplant. : 1578 -1585 .
Delgado-Borrego, A., Liu, Y. S., Jordan, S. H. és mtsai: Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl., 2008, 14 , 193–201.
Jordan S. H. , 'Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance ' (2008 ) 14 Liver Transpl. : 193 -201 .
Trail, K. C., McCashland, T. M., Larsen, J. L. és mtsai: Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl. Surg., 1996, 2 , 276–283.
Larsen J. L. , 'Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation ' (1996 ) 2 Liver Transpl. Surg. : 276 -283 .
Wahlstrom, H. E., Cooper, J., Gores, G. és mtsai: Survival after liver transplantation in diabetics. Transplant. Proc., 1991, 23 , 1565–1566.
Gores G. , 'Survival after liver transplantation in diabetics ' (1991 ) 23 Transplant. Proc. : 1565 -1566 .
Piquer, S., Hernandez, C., Enriquez, J. és mtsai: Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J. Lab. Clin. Med., 2001, 137 , 38–42.
Enriquez J. , 'Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon ' (2001 ) 137 J. Lab. Clin. Med. : 38 -42 .
Cua, I. H., Hui, J. M., Bandara, P. és mtsai: Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 2007, 46 , 66–73.
Bandara P. , 'Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines ' (2007 ) 46 Hepatology : 66 -73 .
Bonora, E., Formentini, G., Calcaterra, F. és mtsai: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care, 2002, 25 , 1135–1141.
Calcaterra F. , 'HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study ' (2002 ) 25 Diabetes Care : 1135 -1141 .
Fartoux, L., Poujol-Robert, A., Guechot, J. és mtsai: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut, 2005, 54 , 1003–1008.
Guechot J. , 'Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C ' (2005 ) 54 Gut : 1003 -1008 .
Hui, J. M., Sud, A., Farrell, G. C. és mtsai: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression (corrected). Gastroenterology, 2003, 125 , 1695–1704.
Farrell G. C. , 'Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression (corrected) ' (2003 ) 125 Gastroenterology : 1695 -1704 .
Hui, J. M., Kench, J. G., Chitturi, S. és mtsai: Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology, 2003, 38 , 420–427.
Chitturi S. , 'Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C ' (2003 ) 38 Hepatology : 420 -427 .
Nemes, B., Doros, A., Holzbauer, Á. és mtsai: Expression pattern of molecular chaperones after liver transplantation in hepatitis C positive recipients. Relation to serum HCV-RNA titers. IMAS, 2009, 1 , 35–40.
Holzbauer Á. , 'Expression pattern of molecular chaperones after liver transplantation in hepatitis C positive recipients. Relation to serum HCV-RNA titers ' (2009 ) 1 IMAS : 35 -40 .
Foxton, M. R., Quaglia, A., Muiesan, P. és mtsai: The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. American Journal of Transplantation, 2006, 6 , 1922–1929.
Muiesan P. , 'The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C ' (2006 ) 6 American Journal of Transplantation : 1922 -1929 .
Paradis, V., Perlemuter, G., Bonvoust, F. és mtsai: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology, 2001, 34 , 738–744.
Bonvoust F. , 'High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis ' (2001 ) 34 Hepatology : 738 -744 .
Romero-Gomez, M., Del Mar Viloria, M., Andrade, R. J. és mtsai: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 2005, 128 , 636–641.
Andrade R. J. , 'Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients ' (2005 ) 128 Gastroenterology : 636 -641 .
Durante-Mangoni, E., Zampino, R., Marrone, A. és mtsai: Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment. Pharmacol. Ther., 2006, 24 , 1349–1357.
Marrone A. , 'Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients ' (2006 ) 24 Aliment. Pharmacol. Ther. : 1349 -1357 .
Matsuzawa, Y., Funahashi, T., Kihara, S. és mtsa: Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2004, 24 , 29–33.
Kihara S. , 'Adiponectin and metabolic syndrome ' (2004 ) 24 Arterioscler. Thromb. Vasc. Biol. : 29 -33 .
Kugelmas, M., Hill, D. B., Vivian, B. és mtsai: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology, 2003, 38 , 413–419.
Vivian B. , 'Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E ' (2003 ) 38 Hepatology : 413 -419 .
Dharancy, S., Malapel, M., Perlemuter, G. és mtsai: Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology, 2005, 128 , 334–342.
Perlemuter G. , 'Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection ' (2005 ) 128 Gastroenterology : 334 -342 .
Aytug, S., Reich, D., Sapiro, L. E. és mtsai: Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology, 2003, 38 , 1384–1392.
Sapiro L. E. , 'Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes ' (2003 ) 38 Hepatology : 1384 -1392 .
Kawaguchi, T., Yoshida, T., Harada, M. és mtsai: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol., 2004, 165 , 1499–1508.
Harada M. , 'Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3 ' (2004 ) 165 Am. J. Pathol. : 1499 -1508 .
Breuer, T., Sápi, E., Hartyánszky, I. L. és mtsai: Impact of blood glucose values in patients with and without insulin treatment following paediatric cardiac surgery. IMAS, 2010, 2 , 10–16.
Hartyánszky I. L. , 'Impact of blood glucose values in patients with and without insulin treatment following paediatric cardiac surgery ' (2010 ) 2 IMAS : 10 -16 .